newsfilter
← Latest News
GlobeNewswire·

Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress

Two NDA submissions expected by mid-February 2026 for ulixacaltamide in essential tremor and relutrigine in SCN2A/8A-DEEs, both with Breakthrough Therapy Designation from the FDA Multiple registrational readouts